Migraine

GammaCore Sapphire, the newest version of gammaCore—a noninvasive vagus nerve stimulator—is now available in the United States to treat patients with migraine and episodic cluster headache.

Approximately 43% of patients using the Migraine Buddy app reported experiencing anxiety and/or depression during at least 1 migraine attack.

Patient with chronic migraine were more likely to have aggression, anger, and hostility. Comorbid aggression may help to identify suicidality in migraine patients.

Building on prior research drawing a link between migraine and fibromyalgia comorbidity, a new study has found that fibromyalgia exacerbates depressive symptoms, migraine intensity, and migraine-related disability.

A recent review evaluated current data on the effects of sex hormones on transient receptor potential channels, which contribute to the sensitization in migraine and chronic pain syndromes.

Despite patients with migraine being younger and having fewer indicators for predicting readmission, they had an increased risk of 30-day hospital readmission due to pain.

The authors of a recent editorial explained that the higher prevalence of migraine in obese individuals may be due to a common etiological factor, because both conditions are linked to inflammatory processes.

PatientPoint and Migraine Again have partnered to provide educational video content in nearly 5000 primary care and obstetrics/gynecology practices nationwide, offering patients and physicians insight into better managing migraine.

While the prevalence of migraine was significantly higher among patients with diabetes, the disease, itself, was not associated with a greater risk of migraine.

Just one-third of respondents of the Migraine in America 2018 survey, conducted by Health Union, are aware of calcitonin gene-related peptide (CGRP) inhibitors. Those who did know about the therapies had questions and concerns, such as cost, insurance coverage, and side effects.

The once-monthly self-injected calcitonin gene-related peptide (CGRP) inhibitor is now approved in the European Union, Switzerland, the United States, and Australia.

Previous research has revealed that poor sleep quality is common among those with migraine. New study results point to similar findings for those with probable migraine—a subtype of migraine that is common in the general population.

Researchers found that people who suffer from chronic migraine experience visual quality of life impacts comparable to other neoro-opthalmic disorders.

A recent study investigated the associations of migraine with pain symptoms among outpatients with major depressive disorder during a 10-year period, finding that migraine treatment should be integrated into treatment for depression to improve patients’ pain symptoms and health-related quality of life.

Researchers observed that migraine was associated with an increased risk of developing a cochlear disorder, especially tinnitus.

Recent data shows how common combination coprescribing of opioids with a triptan or a serotonergic antidepressant was just 2 years prior to an FDA warning about the risk of serotonin syndrome from such coprescribing.

The Institute for Clinical and Economic Review (ICER) has released their final evidence report evaluating the effectiveness and value of calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients who suffer from episodic or chronic migraine.

Through a smartphone app, SensorRx is utilizing patient-collected data and linking it to the patient’s electronic health record, allowing the physician to better understand a patient’s migraine trends and improve outcomes.

As researchers examined what food and drinks were most commonly linked to migraine and tension-type headache in Malaysian patients, they found that coffee and chocolate were reported most often.

According to Amgen and Novartis, their calcitonin gene-related peptide inhibitor has demonstrated safety and efficacy in a 1-year study in chronic migraine and reinforced safety and tolerability in a 3-year interim analysis from an ongoing 5-year study in episodic migraine.

While it is known that heightened estrogen levels are linked to an increased prevalence of migraine in women, new research suggests that the hormone plays an equally important role in causing migraine among men.

The average duration of a migraine was found to be independent from the presence of allergy, as well as the frequency of the cephalalgy attacks, and the localization of the pain.

For many patients with migraine, cannabis served as a substitute for other pain medications, including opioids.